Digital success doesn ’t start with the tech

  We all know that the biggest hurdle for any transformation project is culture. No wonder then that many of us working within digital transformation have hoped to open minds and inspire a new way of working through big, buzzy projects.    There ’s now even a blueprint for this type of innovation: find a tech partner, design a pilot with a trending technology, and ‘signal’ to peers, rivals and shareholders that you’re embracing the future with a flashy press release.   But when we sat down with Dan Rothman the Chief Digital Officer, Dainippon Sumitomo Pharma and Milind Kamkolkar, Chief Digital Officer, Cellarity, at the eyeforpharma Barcelona Virtual summit, they emphatically underlined that this common approach is exactly the problem.   Don ’t get distracted  When we are seduced by this way of working, we wind up doing more harm than good.    If we are being honest with ourselves, many of these projects begin with the wrong motivation at their core. Rather than impressing potential partners, this actually signals that you ’re not ready for change. Kamkolkar points out: “I think many of us in the entrepreneurial community would prefer to see outcomes rather than who you are partnering with, because honestly, who cares?”  Yes, pilots can be useful to raise awareness of a particular technology, but usually we don ’t connect them to an overall strategy for change. F...
Source: EyeForPharma - Category: Pharmaceuticals Authors: Source Type: news

Related Links:

By JESSICA DaMASSA, WTF HEALTH Healthcare startups serving the Medicaid population are FINALLY catching the attention of investors and, this time, it’s for improving access to mental health services. Brave Health’s CEO Anna Lindow and I catch up in-person at HLTH 2021 – under super-secret embargo – to talk about Brave’s $10M Series B funding which was just announced today. We get into Brave Health’s virtual-first approach to therapy, psychiatry, and outpatient addiction services, its tech underpinnings (which Anna hopes makes her services feel like “magic” to patients ...
Source: The Health Care Blog - Category: Consumer Health News Authors: Tags: Health Tech WTF Health Anna Lindow Brave Health Jessica DaMassa Medicaid Source Type: blogs
Conditions:   Alcohol Use Disorder;   Substance Use Disorders Intervention:   Behavioral: Dialectical behavioral therapy skills training (DBT-ST) Sponsors:   Centre for Addiction and Mental Health;   University of Missouri, St. Louis Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Alcohol Use Disorder;   Alcoholism;   Alcohol Addiction Interventions:   Drug: Oxytocin nasal spray;   Drug: Naltrexone Pill;   Drug: Placebo Sponsors:   Central Institute of Mental Health, Mannheim;   Heidelberg University - Institute of Medical Biometry (IMBI);   Heidelberg University - Coordination Centre for Clinical Trials (KKS) of Heidelberg University;   German Federal Ministry of Education and Research Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Notice NOT-HL-21-039 from the NIH Guide for Grants and Contracts
Source: NIH Funding Opportunities (Notices, PA, RFA) - Category: Research Source Type: funding
Notice NOT-HL-21-040 from the NIH Guide for Grants and Contracts
Source: NIH Funding Opportunities (Notices, PA, RFA) - Category: Research Source Type: funding
This study examines potential correlations between substance use patterns, psychopathological symptoms, and attention performance in methamphetamine-dependent inpatients with and without a history of attention deficit hyperactivity disorder in childhood.  Sixty male and 16 female inpatients in two treatment centers were examined. Pre-treatment, participants were interviewed regarding socio-demographic characteristics, medical history, completed measurements for intellectual capability, and symptomology of attention deficit hyperactivity disorder in childhood. Pre- and post-treatment cognitive function and psychopathol...
Source: International Journal of Mental Health and Addiction - Category: Addiction Source Type: research
Several new synthetic cathinones, which mimic the effect of classical psychostimulants such as cocaine or MDMA, have appeared in the global illicit drug market in the last decades. In fact, the illicit drug market is continually evolving by constantly adding small modifications to the common chemical structure of synthetic cathinones. Thus, the aim of this study was to investigate the in vitro and in vivo structure–activity relationship (SAR) of six novel synthetic cathinones currently popular as recreational drugs, pentedrone, pentylone, N-ethyl-pentedrone (NEPD), N-ethyl-pentylone (NEP), 4-methyl-pentedrone (4-MPD)...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Notice NOT-MD-22-001 from the NIH Guide for Grants and Contracts
Source: NIH Funding Opportunities (Notices, PA, RFA) - Category: Research Source Type: funding
On a morning Zoom call, a group of Canadian mothers give their full attention to a young man from the Drug User Liberation Front. At 26, Jeremy Kalicum is the age some of their kids would be if they had not died of accidental overdoses. “We’re just sick of it. We’re sick of our friends dying.”Kalicum’s tone is urgent as he walks the moms through a PowerPoint presentation explaining why the Liberation Front, known as DULF, wants to protest on International Overdose Awareness Day and hand out illicit drugs. These wouldn’t be the kind that killed their sons and daughters, he assures them; t...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized feature nationpod photography Source Type: news
Expert Opin Pharmacother. 2021 Oct 25. doi: 10.1080/14656566.2021.1998456. Online ahead of print.NO ABSTRACTPMID:34693842 | DOI:10.1080/14656566.2021.1998456
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Authors: Source Type: research
More News: Addiction | Environmental Health | Marketing | Pharmaceuticals | Sugar